Pharmacological action not specified

This product is a third-generation cephalosporin antibiotic. It has high antibacterial activity against Escherichia coli, Klebsiella pneumoniae and other Enterobacteriaceae, Haemophilus influenzae, Pseudomonas aeruginosa, etc. It also has good antibacterial effects on nitrate-negative bacilli, Alcaligenes, etc. Most beta-lactamases produced by bacteria are highly stable, so it can still have antibacterial activity against multi-drug resistant strains of most of the above-mentioned Gram-negative bacilli. Gram-positive cocci such as pneumococci and hemolytic streptococci are highly sensitive to this product, but this product has only moderate activity against staphylococci, while enterococci and methicillin-resistant Staphylococci are often resistant to this product. This product has certain antibacterial activity against anaerobic bacteria such as Peptococcus and Peptostreptococci, but has poor antibacterial effect against Bacteroides fragilis. Its mechanism of action is to bind to penicillin-binding proteins (PBPs) on the bacterial cell membrane, acylate the transpeptidase, inhibit the synthesis of the bacterial septum and cell wall, affect the cross-linking of the cell wall mucopeptide components, inhibit cell division and growth, elongate the bacterial morphology, and finally dissolve and die.

This product is a second-generation cephalosporin for intravenous or intramuscular injection. It has a wider antibacterial spectrum against Gram-negative bacilli than the first-generation cephalosporins. It has good antibacterial activity similar to cefoxitin against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter, Providencia and Enterobacter, but its activity against indole-positive Proteus, Morganella, Providencia and some Klebsiella is lower than that of cefoxitin. It has satisfactory activity against gonococci of influenza bacilli, including beta-lactamase-producing strains. Like other second-generation cephalosporins, Pseudomonas, Serratia and Acinetobacter are resistant to this product. This product is effective against most Gram-positive cocci, and its activity against Staphylococcus aureus is similar to that of cefoxitin and cefuroxime, but lower than that of cefoxitin, cephalothin and cefazolin. 90% of the strains can be inhibited by this product at a concentration of 4.0 to 8.3 mg/L. Most streptococci, including Streptococcus pneumoniae, Streptococcus pyogenes and group B streptococci, are sensitive to this product. Staphylococcus epidermidis is relatively resistant to this product. Fecal Streptococcus, Staphylococcus aureus and methicillin-resistant strains of Staphylococcus epidermidis are all resistant to this product. The activity of this product against anaerobic bacteria has not been well studied, and Bacteroides fragilis is resistant to this product. The minimum bactericidal concentration (MBC) of this product for Staphylococcus aureus, group B streptococci and Escherichia coli is significantly higher than its minimum inhibitory concentration (MIC). This product is very stable to type I beta-lactamase, but can be slowly hydrolyzed by type IIIa, IIIb and V beta-lactamase, while only type IV beta-lactamase is sensitive.

Unspecified

The third generation cephalosporin antibiotics have a broad-spectrum antibacterial effect and are highly active against Enterobacteriaceae. The MIC90 for Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Citrobacter fluorescens, indole-positive Proteus, Providencia and Serratia is between 0.12 and 0.25 mg/L. It has a strong antibacterial effect on Haemophilus influenzae, Neisseria gonorrhoeae and Neisseria meningitidis, and also has a good effect on hemolytic streptococci and pneumococci. The MIC for Staphylococcus aureus is 2 to 4 mg/L. Methicillin-resistant Staphylococci and enterococci are resistant to this product. Most Bacteroides fragilis are resistant to this product.